Per una migliore esperienza, mantieni il tuo browser aggiornato. Controlla qui le ultime versioni.

June 2022
Axxam announces license agreement with iPS Academia Japan to enhance further iPSC-based discovery services

Our Zoner Axxam, a privately-owned innovative Partner Research Organization (iPRO), has entered into a non-exclusive license agreement with iPS Academia Japan, Inc. (“AJ”) which was formed to facilitate the application of induced pluripotent stem cell (iPSC) technologies of Kyoto University. The license agreement allows Axxam to provide state of the art discovery services using human iPSCs and iPSC-derived cells to its clients.
Human iPSCs and iPSC-derived differentiated cells will be used as an extremely relevant cellular background for the development of highly-customized in-vitro assays for relevant target classes and molecular pathways in screening projects to identify new hits and leads in the early phases of the drug discovery process, as well as to assess and validate relevant targets.

The use of human iPSC-derived differentiated cells is of increasing importance especially in drug discovery projects for CNS diseases where the use of human primary cells is not possible or extremely limited.
Offering high-quality services including high-throughput screening (HTS) with plate optical detection (in 1536 and 384 well formats) and complementary technological readouts such as radiometric screening (SPA, flash-plate), the DSC business unit will cooperate in unison with the team in Milan responding to the increasing requests from the market for capacity and capabilities in early drug discovery research and specifically in facing challenging HTS projects.

The IMAX Discovery business unit will continue offering its clients and partners integrated solutions across the entire discovery process starting from flavor, fragrance and cosmetic target identification and validation up to the selection and development of new bioactive compounds by providing services, tools and integrated solutions tailored to the specific needs of its clients and partners.
Stefan Lohmer
CEO at Axxam

Axxam’s continuous mission is to support our clients and partners tackling the most challenging diseases that are affecting humanity. The combination of most innovative approaches to develop in-vitro assays with the possibility to work on more relevant models of human diseases based on iPSCs will make the difference against neuronal and neurodegenerative diseases, such as Parkinson’s and Alzheimer’s, but also on cardiac diseases, inflammation, fibrotic diseases, retinal diseases, pain disorders and many others.